

2026 Investor Presentation

www.OrthoPediatrics.com

Disclaimer

Forward-Looking Statements

All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements speak only as of the date of this presentation. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others; We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in our quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2026, and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this presentation.

Use of Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Free cash flow, which we reconcile to "Net cash provided by (used in) operating activities" is cash flow from operations reduced by "Capital expenditures". Adjusted loss per share in this presentation represents diluted loss per share on a GAAP basis, excluding intangible asset impairment, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this presentation represents net loss, plus interest expense, net plus other expense (income), net plus income tax charge (benefit), depreciation and amortization, intangible asset impairment, stock-based compensation expense, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and the cost of minimum purchase commitments. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. The Company believes the non-GAAP measures provided in this presentation enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company's operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management's use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company's presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using these adjusted measures on a supplemental basis. The Company's definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules included contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.



OrthoPediatrics was founded on the **cause** of impacting the lives of children with orthopedic conditions

+ 1,425,000

pediatric patients treated since inception[1]

01 Children's **unique clinical conditions**

02 Existing solutions are **re-purposed from adult implants**


03 Limited development of **new technologies**

04 No **specialized sales force** in Pediatric Orthopedics

05 Limited industry support of clinical **education**

Re-Purposed Adult Plate

Screws through growth plate



01 **Product development focused** exclusively on pediatric patients

02 **Broadest pediatric specific portfolio** in the industry

03 Delivering first in market **novel surgical solutions**

04 Only global **commercial channel to market**

05 Leading provider of surgeon **clinical education**

PediLoc Femur

Screws parallel to growth plate



- Enhance surgeon confidence
- Increase surgical efficiency
- Improve surgical accuracy

Innovative Technology

95+ unique pediatric systems

Consistent **cadence** of innovative product launches

Expanding suite of **enabling** technologies

Internal **R&D**, acquisitions, and partnerships

Commercial Execution

Only global sales & distribution channel

Serve **100% of top children's hospitals** in the U.S.

~240 domestic field representatives

Sell in **over 75** countries around the world

Clinical Education

Commitment to clinical education

Leading **sponsor** of critical pediatric medical societies

>700 clinical product/education events per year


Founder of Foundation of Advancing Pediatric Orthopedics

Consistent YoY Growth

Since Inception[1]

[1] Excluding COVID-impacted 2020

U.S. Addressable Market[1] — $2.8B



Competitive Dynamics

01 Large incumbents repurpose adult implants

02 Require specialized sales force

03 Lack of focus on pediatric conditions



[1] Management's Estimate as of January 2025 updates to IMS data from 2016

01 

Laser focus on high-volume Children's Hospitals that treat majority of pediatric patients

02 

Provide a **broad product portfolio** uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs

03 

Deploy instrument sets and provide unparalleled sales support


04 

Expand addressable market through aggressive investment in **R&D and select M&A opportunities**

05 

Train next generation of pediatric orthopedic surgeons

Current U.S. Target Market[1] — $1.6B





Comments

01 ~1,700 Fellowship Trained Pediatric Surgeons

02 Majority of Pediatric Centers are Teaching Hospitals

03 Centers Treat Most Complex Pediatric Conditions

04 ~80% of Pediatric Surgeons time is Non-Surgical

[1] Management's Estimate as of January 2025 updates to IMS data from 2016

20 Years of Foundation Building

2008 — LAUNCH — **Cannulated Screws**



2012 — LAUNCH — **PediNail™ System**



2016 — LAUNCH — **Hip Systems**



2020 — LAUNCH — **RESPONSE™ Scoliosis**



2020 — ACQUIRE — **Orthex® External Fixation**




2025 — ACQUIRE — **MD Orthopedics® Bracing**



95+ Systems

Broadest Portfolio across:

Trauma & Def
Scoliosis
Sports Med
External Fixation
Specialty Bracing
Enabling Tech


Cannulated Screw Systems
PediFrag™
Pediatric Specific Clavicle Plates
BandLoc System
Single, Duo
FG SCFE
Screw System
Locking Proximal
Femur Plate
System (LPF)
RESPONSE™
Spine System
Trans-Physeal
Locking Screws
PediNail™ Pediatric
Femoral Nail
PediFlex™
Flexible Nailing System
FD Nailing System
PediLoc® Locking
Cannulated Blade Plate
• 3.5mm and 4.5mm cannulated plates
• infant, child & adolescent sizes
• 90, 100 & 130 degree plates
• 130 degree plate for fracture fixation
and valgus osteotomies
PediLoc® Extension
Osteotomy Plate (PLEO)
PNP - Femur Pediatric
Nailing Platform
• 7, 8, 9, 10, 11 & 12mm diameters
• 20 - 42cm lengths
PediPlates®
Distal Femoral
Osteotomy System
(DFOS)
Orthex
External Fixation
& Hexpod System
PediFrag™ System
2.7mm, 3.5mm
PediFoot™
2.7mm, 3.5mm
Vilex Rail Fixation System
PediLoc® Tibia
Locking Plate System
DISTRIBUTED BY
CONNEXION

Surgeon-led Innovation

- New products originate from unmet clinical needs identified by pediatric orthopedic surgeons

Building Platforms

- Focus on platform & product family development rather than isolated products

Multi-year super cycle

- Entered a multi-year product super cycle, with multiple launches expected over several years

Trauma & Deformity

- 3P™ Small | Mini
- PNP | Retro
- 3P™ | Knee
- PNP | SD
- Pin to Bar Ex-Fix

Scoliosis

- VerAxis™ Scoliosis
- eLLi™

OPSB

- Tractor Fix

Enabling Tech

- Predictive Planning


Entering a "Super-Cycle" of Differentiated Product Launches

PNP | Tibia




Launched

Response™ Rib & Pelvic



GIRO™




Launched

DF2®




VERTEGLIDE™



Launched

3P™ Hip Platform



PediHip® Rigid Hippo Brace




Iota Motion




Limited

Playbook Surgical ™



Entering a "Super-Cycle" of Differentiated Product Launches


3P™ Small | Mini




Knee 'Tractor FIX




eLLi™



PNP | SD



3P™ | Knee




Limited — **Limited** — **1H27** — **2H27**


Traxio™ Halo Gravity



PNP | Retro



Predictive Planning



VerAxis™ Scoliosis




Pin to Bar Ex-Fix



Total Revenue ($M)

+20% CAGR



Accelerating Sales Growth Post-IPO
Through Strategic Investment and Innovation


	2016	2025	CAGR
U.S. Independent Sales Consultants	90	232	11%
Instrument Set Deployments	$7M	$17M	10%
Unique Pediatric Systems	17	87	20%
Intl. Independent Sales Agencies	0	16	Fav

- Accelerate Revenue Growth
- Increase Hospital Penetration
- Improve Profitability
- Leverage Balance Sheet

[1] Impacted by COVID

Set Deployment Efficiencies

Reducing set deployments as a percentage of revenue while continuing to take share



[1] Boston O&P Acquisition

[2] Represents the midpoint of the Company's 2026 revenue guidance range of $270.0 to $273.0 million and expected annual set deployment

Improving ROI on Sets Deployed

01

Super Cycle Product Launches

- Products with defined clinical needs & stronger financial profile (higher ASPs and gross margins, less capital required)

02

Higher Utilization

- Market share gains and ramping in utilization of previous deployments creates leverage

03

Platform Systems

- Systems designed to utilize similar parts produces platform synergies and capital efficiencies

Strategic Acquisitions & Partnerships

Partnership **Acquisition**

2017 — FIREFLY TECHNOLOGY



2019 — ORTHEX



2020 — ApiFix



2021 — 7D Surgical



2022 — MD ORTHOPAEDICS



2022 — Pega Medical



2023 — ORA Medical



2023 — MedTek Concepts



2023 — RHINO



2024 — boston ORTHOTICS & PROSTHETICS



2026 — OSSIO



Aggressive market-based clinic expansion strategy

18 new markets by 2027 (27 total)

Accelerate R&D with increasing number of YoY launches

Launch 4 products in 2024 and 5 in 2025

Scale OPSB selling channel and sales force – grow with current portfolio of products

Doubling size of the sales channel

Pace of Market Expansion

+4 markets
in 2025

+6 markets
in 2026


+8 markets
in 2027

OPSB clinics expected to be in 27 territories in 2027 out of 80 target territories

	Greenfield	Acqui-Hire
Initial Investment	$200k-$500k	$500K-$1M
EBITDA Goal	Positive EBITDA by end of first full year	Positive EBITDA by end of first full year
FCF Goal	After first full year	Within first year
ROI Goal	Break even ROI by Year 3	Break even ROI by Year 5
Time to Ramp	6 months for licensure, insurance, lease, clinicians, training, etc.	Immediate licensure, insurance, location, clinicians, training etc.
IRR	40%	25%

1-4 Clinics per market expected

U.S. Potential Target Market [1] — $1.0B



OPSB Opportunity – **$2.2B**



Levity Device for Gait Assist



Dynamic Femur Fracture (DF2) Brace

[1] Management's Estimate as of January 2026

01 OP Hands-on sales training and support

- Annually invests 3% of sales on clinical education
- Conducts >700 product/training sessions per year

02 Market development

- Fosters early relationships with young surgeons and fellows to drive sustainable growth


03 Continuous education

- Major Sponsor of the prominent pediatric orthopedic societies

Supporting more than 20 fellowships


Trauma & Deformity

Pediatric Systems



+19% CAGR

Revenue




+22% CAGR

70% of Revenue


Scoliosis

Pediatric Systems



>4X Growth

Revenue




>6X Growth

28% of Revenue

2025 Revenue by Product Family




Strong History of Y/Y Growth ($M)



[1] Impacted by COVID [2] Represents the midpoint of the Company's 2026 revenue guidance range of $270.0 to $273.0 million

Seasonality Drives Stronger Performance in Summer Months and Holiday Periods



($ in Millions)

	FY2023	FY2024	FY2025
Revenue	$148.7	$204.7	$236.3
Growth %	22%	38%	15%
Gross profit	$111.3	$148.6	$172.7
Margin %	75%	73%	73%
Operating expenses	$138.0	$183.6	$211.9
Operating loss	($26.8)	($35.0)	($39.2)
Net (loss) income	**($21.0)**	**($37.8)**	**($39.6)**
EPS diluted	**($0.92)**	**($1.64)**	**($1.69)**

3Q 2025	3Q 2026
$61.2	$72.7
12%	19%
$45.3	$54.0
74%	74%
$54.7	$58.2
($9.4)	($4.2)
($11.8)	**($5.9)**
($0.50)	**($0.25)**

Adjusted EBITDA Reconciliation


($ in Millions)

	Three Months Ended September 30,	
	2025	2026
Net loss	($11.8)	($5.9)
Interest expense, net	1.8	2.6
Other expense (income), net	0.6	-
Income tax charge (benefit)	(0.1)	(0.1)
Depreciation and amortization	5.3	5.6
Intangible asset impairment	2.3	0.6
Stock-based compensation	4.3	4.4
Fair value adj. of contingent consideration	-	(0.8)
Restructuring charges	2.3	-
Tariffs	0.3	0.2
Acquisition-related costs	0.9	0.3
Minimum purchase commitment cost	0.3	-
Adjusted EBITDA	**$6.2**	**$6.9**


	Three Months Ended September 30,	
	2025	2026
Loss per share, diluted (GAAP)	($0.50)	($0.25)
Intangible asset impairment	0.10	0.03
Fair value adj. of contingent consideration	-	(0.03)
Tariffs	0.01	0.01
Restructuring charges	0.10	-
Acquisition-related costs	0.04	0.01
Minimum purchase commitment cost	0.01	-
Adjusted loss per share, diluted (non-GAAP)	**($0.24)**	**($0.23)**

Free Cash Flow ($M)


Total Year



Quarterly



YTD



($ in Millions)
As of September 30, 2026

Assets	
Cash, cash equivalents & short-term investments	$44.9
Accounts receivable	59.5
Inventory (net)	141.9
Other current assets	6.9
Total Current Assets	**253.2**
PP&E (net)	47.0
Intangibles and goodwill	208.9
Total Assets	**$509.1**

Liabilities	
Accounts payable	$24.5
Debt	98.4
Accrued comp. & other liab.	42.1
Acquisition pay. & cont. consideration	4.8
Paid-in capital	637.3
Accumulated deficit (net)	(299.0)
Accumulated other comprehensive loss	1.0
Total Liabilities / Equity	**$509.1**

($ in Millions)

2026 Guidance

	FY2026
Revenue	$270.0 to $273.0
Adjusted EBITDA	~$25.0
Free Cash Flow	Breakeven

Assumptions

	FY2026
2026 Total Revenue Growth %	14% to 16%
Set Deployment	~$10.0



01 Only diversified company focused exclusively on pediatric orthopedics

02 Large, underpenetrated market opportunity in pediatrics

03 Highly concentrated customer base with targeted commercial strategy

04 Broad product portfolio with innovative solutions

05 Only provider committed to pediatric clinical education

06 Dynamic, award-winning corporate culture

07 Proven commercial execution and attractive financial profile



2850 Frontier Drive • Warsaw, IN 46582
ph: 574.268.6379 or 877.268.6339
fax: 574.268.6302
www.OrthoPediatrics.com